Androgen deprivation therapy for prostate cancer: a follow-up study of the patients' survival time.
- Author:
Shi-Ge ZHANG
1
;
Jiu-Lin WANG
2
;
Ye WU
2
;
Ning SHAO
2
;
Di QIAO
2
;
Yi DING
2
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Androgen Antagonists; therapeutic use; Bone Neoplasms; secondary; Disease-Free Survival; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Prostatic Neoplasms; mortality; therapy
- From: National Journal of Andrology 2013;19(12):1103-1106
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the long-term survival and prognosis of prostate cancer patients after treated by androgen deprivation therapy.
METHODSWe conducted a follow-up study of 124 patients with prostate cancer treated by androgen deprivation therapy, and compared the survival times of the patients with different pathological grades and clinical characteristics using Kaplan-Meiers survival curves.
RESULTSThe mean survival time of the 124 patients after androgen deprivation therapy was 5. 912 years, with the median survival time of 7.81 years. The patients with bone metastases showed a shorter survival time than those with non-bone metastasis (P = 0.04). Pathological grades and PSA levels were not prognostic factors. No significant differences were found in the mean survival time between those died of prostate cancer (n = 35) and those from other factors (n = 23) (P = 0.50).
CONCLUSIONBone metastasis is an important prognostic factor in advanced prostate cancer following androgen deprivation therapy, which is more significantly correlated with the survival time of the patients than tumor grades and clinical classification.
